Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
EQL Pharma AB ( (SE:EQL) ) has issued an announcement.
EQL Pharma AB reported a successful year-end with a 45% increase in sales and a 174% rise in operating profit, driven by the acquisition of new products and a significant distribution deal outside Europe. The company has surpassed its five-year growth targets and is poised for continued expansion with a new strategic plan aiming for a 30% sales growth in the coming year.
More about EQL Pharma AB
EQL Pharma AB operates in the pharmaceutical industry, focusing on the development and distribution of niche generic drugs. The company is expanding its market presence with a significant emphasis on non-European markets, as evidenced by its recent distribution agreement in the Gulf countries.
Average Trading Volume: 20,129
Current Market Cap: SEK2.3B
Find detailed analytics on EQL stock on TipRanks’ Stock Analysis page.